Podcast Episodes
Back to Search
Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer
Season 1 Episode 161
Fred Saad describes the results of this trial.
4 years, 8 months ago
Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer
Season 1 Episode 156
Jonathan Rosenberg describes the results of this positive randomised trial.
4 years, 8 months ago
Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer
Season 1 Episode 157
Petros Grivas describes the results of this phase 2 trial.
4 years, 8 months ago
Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC
Season 1 Episode 154
Kim Chi describes the results of this randomised phase 3 study.
4 years, 8 months ago
Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer
Season 1 Episode 155
Matthew Smith describes the results of this phase 3 trial.
4 years, 8 months ago
Episode 153: Overview of PARP inhibition in prostate cancer
Pete Nelson describes mechanism of action and current clinical application in prostate cancer
4 years, 8 months ago
Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging
Season 1 Episode 155
Elizabeth de Vries describes her paper in Annals of Oncology.
4 years, 8 months ago
Episode 151: Bladder Cancer ESMO Guidelines update
Season 1 Episode 153
Joaquim Bellmunt gives an overview of the changes.
4 years, 9 months ago
Episode 150: Comparing the quality of life data in renal trials
Season 1 Episode 150
David Cella unpicks the data across these studies and makes some conclusions.
4 years, 9 months ago
Episode 149: Treatment-free survival for ipilimumab and nivolumab
Season 1 Episode 149
David McDermott describes his Clinical Cancer Research paper on this topic.
4 years, 10 months ago